ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,082.05
0.71%
US Tech 100
20,956.65
0.59%
Dow Jones
44,997.74
0.64%
Brent Oil
75.995
0.10%
Bitcoin
105,781.99
1.97%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. USOTC

  6. Csl Ltd (QX) (CSLLY) Quote

Csl Ltd (QX)

Csl Ltd (QX) (CSLLY)

USOTC
87.74
1.51
( 1.75% )
Updated: 14:57:36
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
87.74
Bid
87.58
Ask
87.80
Volume
49,605
87.045 Day's Range 89.69
83.31 52 Week Range 109.00
Market Cap
84.801B
Previous Close
86.23
Open
89.69
Last Trade
20
@
87.712
Last Trade Time
14:59:02
Financial Volume
$ 4,343,416
VWAP
87.56
Average Volume (3m)
88,012
Shares Outstanding
966,505,458
Dividend Yield
-
PE Ratio
102.41
Earnings Per Share (EPS)
2.73
Revenue
14.69B
Net Profit
2.64B

About Csl Ltd (QX)

CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.csl.com.au
Headquarters
Melbourne, Victoria, Aus
Founded
1916
Csl Ltd (QX) is listed in the Biological Pds,ex Diagnstics sector of the OTCMarkets with ticker CSLLY. The last closing price for Csl (QX) was $86.23. Over the last year, Csl (QX) shares have traded in a share price range of $ 83.31 to $ 109.00.

Csl (QX) currently has 966,505,458 shares outstanding. The market capitalization of Csl (QX) is $83.34 billion. Csl (QX) has a price to earnings ratio (PE ratio) of 102.41.

Ask ADVFN Intelligence (AI)

CSLLY Latest News

More News

Form 3 - Initial statement of beneficial ownership of securities

July 25 2023
Edgar (US Regulatory)

CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient

CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient Awards Program Supports Novel Research of Immunoglobulin Therapy for Neurological Disorders PR Newswire KING OF PRUSSIA, Pa...

June 29 2015
PR Newswire (US)

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015 PR Newswire TORONTO, June 24, 2015 - Data supports prolonged dosing...

June 24 2015
PR Newswire (US)

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A PR Newswire TORONTO, June 24, 2015 Data Presented during Late Breaking Session at...

June 24 2015
PR Newswire (US)

Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers

Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers Panel of experts examines how value of biopharmaceutical technologies is assessed...

June 17 2015
PR Newswire (US)

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress PR Newswire KING OF PRUSSIA, Pa., June 16, 2015 More than 20 abstracts focusing on investigational and...

June 16 2015
PR Newswire (US)

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients...

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD) PR Newswire KING OF...

June 01 2015
PR Newswire (US)

National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award

National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award CSL Behring Recognized for its Longstanding Commitment to Delivering Innovative Products and Programs that...

May 22 2015
PR Newswire (US)

Science, Information, And Technology Driving Evolution Of Global Healthcare

Science, Information, And Technology Driving Evolution Of Global Healthcare Industry serves critical role in advancing healthcare and improving the well-being of patients, says CSL CEO Paul...

May 14 2015
PR Newswire (US)

CSL Behring Awards Young Researchers Around the World to Advance Coagulation Science

CSL Behring Awards Young Researchers Around the World to Advance Coagulation Science PR Newswire MARBURG, Germany, April 23, 2015 CSL Behring Professor Heimburger Award Provides 100,000 Euros in...

April 23 2015
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
12.993.5280235988284.7589.6984.499265485.37390566DR
40.2740.31326458280987.46690.0483.518936586.54011522DR
12-7.0405-7.4282157194894.780595.183.318801288.35119378DR
26-14.036-13.7910705864101.77610983.315068591.03483501DR
52-9.26-9.546391752589710983.314130492.17507466DR
156-1.3101-1.4711943052389.0501110.2571.516576791.49439518DR
260-17.24-16.4221756525104.98117.9871.515883695.48862095DR

CSLLY - Frequently Asked Questions (FAQ)

What is the current Csl (QX) share price?
The current share price of Csl (QX) is $ 87.74
How many Csl (QX) shares are in issue?
Csl (QX) has 966,505,458 shares in issue
What is the market cap of Csl (QX)?
The market capitalisation of Csl (QX) is USD 83.34B
What is the 1 year trading range for Csl (QX) share price?
Csl (QX) has traded in the range of $ 83.31 to $ 109.00 during the past year
What is the PE ratio of Csl (QX)?
The price to earnings ratio of Csl (QX) is 102.41
What is the cash to sales ratio of Csl (QX)?
The cash to sales ratio of Csl (QX) is 18.42
What is the reporting currency for Csl (QX)?
Csl (QX) reports financial results in USD
What is the latest annual turnover for Csl (QX)?
The latest annual turnover of Csl (QX) is USD 14.69B
What is the latest annual profit for Csl (QX)?
The latest annual profit of Csl (QX) is USD 2.64B
What is the registered address of Csl (QX)?
The registered address for Csl (QX) is 45 POPLAR ROAD, PARKVILLE, MELBOURNE, VICTORIA, 3052
What is the Csl (QX) website address?
The website address for Csl (QX) is www.csl.com.au
Which industry sector does Csl (QX) operate in?
Csl (QX) operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc (CE)
$ 0.008
(799,900.00%)
318
RLLVFRelevium Technologies Inc (CE)
$ 0.008
(799,900.00%)
8k
NTBLQNotable Labs Ltd (CE)
$ 0.0199
(19,800.00%)
21.96k
SIRCSolar Integrated Roofing Corporation (PK)
$ 0.0001
(9,900.00%)
5.85M
MRPIMera Pharmaceuticals Inc (CE)
$ 0.0001
(9,900.00%)
4.57M
ISUNQiSun Inc (CE)
$ 0.000001
(-99.90%)
200
JFTHJapan Food Tech Holdings Inc (CE)
$ 0.000001
(-99.50%)
453
JAMNJammin Java Corp (PK)
$ 0.000001
(-99.00%)
156.25k
SGMDSugarmade Inc (CE)
$ 0.000001
(-99.00%)
35.78k
INTKIndustrial Nanotech Inc (PK)
$ 0.000001
(-99.00%)
28.06k
GRLFGreen Leaf Innovations Inc (PK)
$ 0.0001
(0.00%)
219.71M
GMPRGourmet Provisions International Corporation (PK)
$ 0.0001
(0.00%)
159.97M
THBDThird Bench Inc (PK)
$ 0.0001
(-33.33%)
114.99M
AITXArtificial Intelligence Technology Solutions Inc (PK)
$ 0.00285
(-5.00%)
95.85M
PHILPHI Group Inc (PK)
$ 0.0002
(0.00%)
75.28M

Discussion

View Full Feed
mascale mascale 4 minutes ago
Versua Hyper-Stupidity, anti-compliance: "Based on available information, yes, it is lawful for Hiru Corporation (OTCPINK: HIRU) to extract minerals from the Balfour Mine Project in Tasmania, Australia, as they have secured a 50-year mining concession for the site, which allows them to explore, dev
HIRU
learningcurve2020 learningcurve2020 4 minutes ago
“A prospective trial is a medical study that follows a group of people over time to collect data about their health outcomes. The goal of a prospective trial is to determine what factors may contribute to a disease or other outcome.”
NWBO
trd4profit trd4profit 4 minutes ago
Finally looking good here! I love the potential on this one...if they can capture the target 10% of the market..Whoa! GL! You really think there is still hope on that other?
RMSL
Spectra777 Spectra777 4 minutes ago
Based on your high level of board participation, accounting for your chronic negative outlook, I question why you'd want to waste your time hanging around a bunch of losers talking about losing.

For your sake, it would be much better for your mental health to sell and move on.
SEV
facts_matter14 facts_matter14 5 minutes ago
All I have to do is know who the bag holders are, and compare what they say to the FACTS, to figure out who is full of shit.




https://investorshub.advfn.com/uimage/uploads/2025/1/26/boexyIMG_6283.jpeg





.
SRMX
ttottip ttottip 5 minutes ago
I agree with you if the company stops unprecedented dilution.
HOLO
royal1 royal1 5 minutes ago
Where is your news?
HMBL
Investor082 Investor082 5 minutes ago
This ain’t happening, so the best strategy is to preserve your capital and get whatever you can on the UK approval spike. Don’t get too greedy and don’t live in denial expecting cash injection from big pharma.

The social media army are already playing the game (kicking the can) of wa
NWBO
bar1080 bar1080 5 minutes ago
Some things about the William Tyler Allen case were noteworthy. He had a finance degree from Miami of Ohio, a fine school, and was age 27 with a fair amount of experience. Like I often say, the motivations of some players puzzle me. I know some medicines have been associated with increased investing
Flobewan Flobewan 5 minutes ago
WOO HOO, got my first script from Express Scripts, 1 went up a little and 1 came down, big savings of $5.29 for 90 days, but hey get them delivered, plus save $555.01 per month getting rid of BC/BS. What can I buy, what can I buy, LOL
Jahvik Jahvik 5 minutes ago
If we would have saw this volume a couple months ago we'd be looking for a PR lol

HMBL
vlispxpert vlispxpert 5 minutes ago
KULR they finding us ;)
KULR
Lone Clone Lone Clone 6 minutes ago
Aftermath Silver Reports Near Surface High Grade Silver and Copper Results

https://www.newsfilecorp.com/release/238925/Aftermath-Silver-Reports-Near-Surface-High-Grade-Silver-and-Copper-Results

January 30, 2025 8:30 AM EST | Source: Aftermath Silver Ltd.

arizona1 arizona1 6 minutes ago
https://substackcdn.com/image/fetch/w_1244,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F444e08de-dee8-4a4f-b7c0-30995986095f_1800x310.jpeg
hankmanhub hankmanhub 6 minutes ago
Explain how booking the big room prioritizes our chances of gaining MHRA approval?
It is not for "gaining" MHRA approval, It is for spreading the word of the approval and tauting this as the first step in informing the world at large of the this novel Platform that could treat most solid canc
NWBO
Researchfyi Researchfyi 6 minutes ago
Here is a link that goes into the issue of being brittle…

https://www.metallurgyfordummies.com/amorphous-metal.html

Good luck to you.
LQMT
sin vester sin vester 6 minutes ago
Touché
BLLB
Gunner 75 Gunner 75 7 minutes ago
Expects to enter into formal negotiations with a global animal health company in January 2025 and to finalize an agreement in the first quarter of 2025

Wonder what happened to this idea !!??
ZIVO
Laster Laster 7 minutes ago
Stock never holds or gains past 3 pm.
Let’s see if it can even hold $7.
No news from MSFT.
Looks like Wes has absolutely no clue if or when a deal will be announced.
No news means stock will continue to drift lower IMO.
MSFT
janice shell janice shell 7 minutes ago
Thank you. I shall be interested in his answer, if he offers one.
Lone Clone Lone Clone 7 minutes ago
Geologica Discovers Copper Showing at Topley

https://www.newsfilecorp.com/release/238904/Geologica-Discovers-Copper-Showing-at-Topley

January 30, 2025 7:45 AM EST | Source: Geologica Resource Corp.

Vancouver, British Columbia--(Newsfile Corp. - January
Hawk05 Hawk05 7 minutes ago
https://wwwv.tsgh.ndmctsgh.edu.tw/unit/30000/29070
BIEL
Royal Dude Royal Dude 7 minutes ago
What is different here is the Fdic schedule is going public on 2/4/2025 on the Southern District Libor case. Do not believe they want this to go public.
COOP
BullNBear52 BullNBear52 7 minutes ago
One would think.

Your Recent History

USOTC
CSLLY
Csl (QX)
BIT
UC5297
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads